Background: Postoperative bleeding after heart operations is still a common finding, leading to allogeneic blood products transfusion.
Kyowa Kirin Co., Ltd. announced that the company received an approval for partial change of approved indication of G-Lasta [KRN125, generic name: pegfilgrastim (genetical recombination) , long-acting Granulocyte Colony-Stimulating Factor (G-CSF) preparation] according to the additional indication, dosage, and administration for the mobilization of hematopoietic stem cells into peripheral blood in allogeneic blood stem cell transplantation in Japan.
The London patient (participant 36 in the IciStem cohort) underwent allogeneic stem-cell transplantation with cells that did not express CCR5 (CCR5Δ32/Δ32); remission was reported at 18 months after analytical treatment interruption (ATI).
Postpartum haemorrhage (PPH) can be exacerbated by haemostatic failure. We hypothesized that early fibrinogen replacement, guided by viscoelastometric testing, reduces blood product usage and bleed size.
In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged.
Postoperative bleeding remains a frequent complication after cardiovascular surgery and may contribute to serious morbidity and mortality. Observational studies have suggested a relationship between low endogenous...
Gamida Cell announced that the FDA has approved Gamida Cell’s allogeneic cell therapy, Omisirge (omidubicel-onlv), for use in adult and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection
Objective: To determine if fibrinogen concentrate is noninferior to cryoprecipitate for treatment of bleeding related to hypofibrinogenemia after cardiac surgery.
Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade...
Mesoblast Limited announced that the Phase III trial of its allogeneic mesenchymal stem cell product candidate MSC-100-IV (remestemcel-L) in children...